Enveric Biosciences, Inc. (ENVB) Stock Price & Analysis
Enveric Biosciences, Inc. (ENVB) fell 3.47% to USD 1.39 as of September 8, 2026 at 06:55 UTC, according to Nexqual real-time market data.
ENVB last closed at USD 1.39; the session ranged USD 1.36–1.45 on volume of 56,742 shares. Market capitalization is —, with a 52-week range of USD 1.17–13.25 (NCM). Source: Nexqual, September 8, 2026 at 06:55 UTC.
Key Statistics (as of September 8, 2026 at 06:55 UTC)
| Price | USD 1.39 |
|---|---|
| Change | ▼ 3.47% (down) |
| Previous Close | USD 1.39 |
| Open | USD 1.39 |
| Day Range | USD 1.36 – 1.45 |
| 52-Week Range | USD 1.17 – 13.25 |
| Volume | 56,742 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (ENVB)
Nexqual's technical model rates ENVB "STRONG SELL" based on 0 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 06:55 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 49.57 (neutral) |
| vs SMA50 | Below (USD 1.42) |
| MACD | -0.02 (negative) |
From Enveric Biosciences, Inc.'s Latest SEC 10-K Filing (filed 2026-03-27)
Key Strengths & Strategy (as disclosed to the SEC)
- The conduct of the pre-clinical tests must comply with federal regulations, including the FDA's Good Laboratory Practices regulations and the U.S.
- While we believe that our technology, knowledge and experience as well as the scientific resources at our disposal provide us with significant competitive advantages, we face potential competition from many different sources.
Partnerships
- Competitors may use this publicly available information to gain knowledge regarding the design and progress of our development programs.   Special Protocol Assessment   A company may reach an agreement with the FDA under the Special Protocol Assessment, or "SPA", process as to the required design and size of clinical trials intended to form the primary basis of an efficacy claim.
- Enveric is a neuro-pharmaceutical scientific company and as such we do not advocate for the legalization of psychedelic substances nor do we deal with psychedelic substances except within laboratory and clinical trial settings conducted within approved regulatory frameworks.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ADTX | Aditxt, Inc. | USD 0.01 | ▲ 0% |
| ENSC | Ensysce Biosciences, Inc. | USD 0.46 | ▲ 2.93% |
| PALI | Palisade Bio, Inc. | USD 2.09 | ▲ 5.03% |
| RKTO | Rocket One Inc. | USD 0.69 | ▲ 0.48% |
| PHIO | Phio Pharmaceuticals Corp. | USD 1.08 | ▼ 4.42% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 06:55 UTC. This page is informational and not investment advice.